NasdaqCM - Nasdaq Real Time Price USD

Aldeyra Therapeutics, Inc. (ALDX)

3.9400 0.0000 (0.00%)
At close: April 25 at 4:00 PM EDT
4.0000 +0.06 (+1.52%)
Pre-Market: 8:40 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
42,794.0830
42,794.0830
62,679.9870
56,219.5360
34,666.7550
Operating Income
-42,794.0830
-42,794.0830
-62,679.9870
-56,219.5360
-34,666.7550
Net Non Operating Interest Income Expense
5,251.5730
5,251.5730
655.3510
-1,556.7380
-1,611.9740
Other Income Expense
--
--
--
--
-1,754.2650
Pretax Income
-37,542.5100
-37,542.5100
-62,024.6360
-57,776.2740
-38,032.9940
Tax Provision
--
--
--
--
-479.2650
Net Income Common Stockholders
-37,542.5100
-37,542.5100
-62,024.6360
-57,776.2740
-37,553.7290
Diluted NI Available to Com Stockholders
-37,542.5100
-37,542.5100
-62,024.6360
-57,776.2740
-37,553.7290
Basic EPS
-0.64
-0.64
-1.06
-1.07
-1.11
Diluted EPS
-0.64
-0.64
-1.06
-1.07
-1.11
Basic Average Shares
58,943.2050
58,943.2050
58,405.8970
54,042.1030
33,965.9550
Diluted Average Shares
58,943.2050
58,943.2050
58,405.8970
54,042.1030
33,965.9550
Total Operating Income as Reported
-42,794.0830
-42,794.0830
-62,679.9870
-56,219.5360
-36,421.0200
Total Expenses
42,794.0830
42,794.0830
62,679.9870
56,219.5360
34,666.7550
Net Income from Continuing & Discontinued Operation
-37,542.5100
-37,542.5100
-62,024.6360
-57,776.2740
-37,553.7290
Normalized Income
-37,542.5100
-37,542.5100
-62,024.6360
-57,776.2740
-35,821.9186
Interest Income
7,323.0080
7,323.0080
2,349.4490
185.3630
292.2240
Interest Expense
2,071.4350
2,071.4350
1,694.0980
1,742.1010
1,904.1980
Net Interest Income
5,251.5730
5,251.5730
655.3510
-1,556.7380
-1,611.9740
EBIT
-35,471.0750
-35,471.0750
-60,330.5380
-56,034.1730
-36,128.7960
EBITDA
-35,208.2950
-35,208.2950
-60,071.8310
-55,769.9930
-36,072.5750
Reconciled Depreciation
262.7800
262.7800
258.7070
264.1800
56.2210
Net Income from Continuing Operation Net Minority Interest
-37,542.5100
-37,542.5100
-62,024.6360
-57,776.2740
-37,553.7290
Total Unusual Items Excluding Goodwill
--
--
--
--
-1,754.2650
Total Unusual Items
--
--
--
--
-1,754.2650
Normalized EBITDA
-35,208.2950
-35,208.2950
-60,071.8310
-55,769.9930
-34,318.3100
Tax Rate for Calcs
--
--
--
--
0.0000
Tax Effect of Unusual Items
--
--
--
--
-22.4546
12/31/2020 - 5/2/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARDX Ardelyx, Inc.
6.31
-1.87%
 
ALXO ALX Oncology Holdings Inc.
16.87
+4.01%
 
MCRB Seres Therapeutics, Inc.
0.7427
+1.81%
 
SNDX Syndax Pharmaceuticals, Inc.
20.57
-1.06%
 
CTMX CytomX Therapeutics, Inc.
1.6000
-1.84%
 
ACRV Acrivon Therapeutics, Inc.
8.47
-10.84%
 
TGTX TG Therapeutics, Inc.
13.91
-0.50%
 
ADMA ADMA Biologics, Inc.
6.44
-0.31%
 
IKT Inhibikase Therapeutics, Inc.
1.9000
+1.60%
 
TARA Protara Therapeutics, Inc.
3.0500
+8.16%